

Rohan Satishkumar, Vladimir Reukov and Alexey Vertegel

#### Introduction

- Antibiotics traditionally used as chemotherapeutic agents to treat bacterial infections
- Recent statistics (CDC, 2006) indicate about 2 million cases of antibiotic-resistant infections each year; 90,000 patients die annually from such infections.
- \$30 billion dollars spent on the cumulative effects of antimicrobial resistance each year (including multiple drug regimens, extra hospital day and additional medical care).





## **Antimicrobial proteins and peptides**

#### **Advantages**

- Antibiotic-free approach
- Broad spectrum of antimicrobial action
- Peptides function as immunomodulators<sup>1</sup>
- Short treatment time

E.g – Lysozyme, Lactoferrin, Defensins, Lactoperoxidase, Cathelicidin


#### **Disadvantages**

- Systemic toxicity
- Low stability
- Delivery issues




## Nanoparticles – Targeting and delivery

- Bioavailability
- Minimum diffusional limitation
- High surface area to volume Effective loading
- Specificity



#### Intrinsic properties of nanoparticles – Size, Charge etc







## Study 1: To study the effect of nanoparticle charge in the targeting of antimicrobial proteins to grampositive bacteria

| Sample                         | Mean diameter of particles* (nm) | Area per<br>charge<br>group*      | Surface<br>charge<br>density<br>(groups/cm²) | No. of<br>functional<br>groups per<br>particle |
|--------------------------------|----------------------------------|-----------------------------------|--|--|
| Aliphatic amine particles      | 20                               | 65Å <sup>2</sup> /NH <sub>2</sub> | 15.38*10 <sup>12</sup>                       | 1930   |
| (+vely<br>charged)             |                                  |                                   |  |  |
| R-CH <sub>2</sub> CI particles | 20                               | 4848 Ų/R-<br>CH <sub>2</sub> CI   | 2.07*10 <sup>12</sup>                        | 26   |
| (-vely charged)                |                                  | 2194 Ų/R-S0 <sub>3</sub> -        | 4.5*10 <sup>12</sup>                         | 56   |




<sup>\*</sup> Data supplied by manufacturer

#### **Overview**









Antimicrobial enzyme, e.g. lysozyme

Covalent conjugation to the surface of nanoparticle



Removal of adsorbed protein using non-ionic surfactants (E.g Tween 20)





Antibacterial assay activity against free enzyme



## Schematic - Protein conjugation to nanoparticles


#### Conjugation to aminated nanoparticles

#### Conjugation to chloromethylated nanoparticles

Satishkumar R and Vertegel A – Biotechnology and Bioengineering, March 2008 (in press)




## Rate of enzymatic activity - Bacterial lysis assay



Bacterial cell substrate – Gram-positive; Micrococcus lysodeikticus



## Effect of nanoparticle charge on bacteriolytic activity



Satishkumar R and Vertegel A – Biotechnology and Bioengineering, March 2008 (in press)




## **Zeta potential analysis**

| Sample  | Zeta potential (mV) |  |
|---|---------------------|--|
| Bacterial substrate                                     | - 27.8 ± 1.1        |  |
| Lysozyme conjugated to positively charged nanoparticles | + 31.5 ± 1.7        |  |
| Lysozyme conjugated to negatively charged nanoparticles | - 32.0 ± 1.6        |  |

- Correlation between charge and bacteriolytic activity
- Targeting better for positively charged nanoparticles



## Activity assay with low molecular weight substrate



• PNP-(GlcNAc)<sub>5</sub> is a chromogenic pentachiteoside that serves as an alternative substrate for lysozyme



## **Conclusions**

- Charge-directed targeting
- Higher antibacterial efficiency than free enzyme against a Grampositive bacterium, Micrococcus lysodeikticus for positively charged protein-nanoparticle conjugates.





# Study 2: To test effectiveness of antibacterial activity of protein-nanoparticle conjugates against Gram-negative bacteria

E.g. of Gram negative bacterium; Escherichia coli, Salmonella, Enterobacteriaceae, Pseudomonas aeruginosa






#### **Bacterial cell wall** a Lipoteichoic Teichoic acid acid Peptidoglycan Gram Positive Cytoplasmic membrane -Lipopolysaccharide Porin Outer → Outer membrane Membrane Lipoprotein Peptidoglycan Periplasm Gram Cytoplasmic membrane Negative



## Pseudomonas aeruginosa

- Gram-negative bacterium
- Opportunistic pathogen
- Multi-drug resistant
- Low permeability of cell wall
- Biofilms





#### 50 percent death in Immunocompromised patients








#### **Materials and methods**

- Pseudomonas aeruginosa (ATCC® 10145) was prepared in nutrient broth and samples were grown to a mid-log phase
- Cell cultures were then centrifuged at 12000 x g and resuspended in 10mM potassium phosphate buffer.
- Cells were incubated with sample conjugates at 37 C with gentle shaking
- Aliquots of 100ul was taken at different time points (after 3, 8, 16 hrs) and then grown on agar in order to determine the number of colony forming units (CFU)






## Antimicrobial assay - CFU method



- Covalent coupling using Glutaraldehyde coupling
- Bacteriostatic
- Toxicity concern




## Antimicrobial assay - CFU method



- Covalent coupling by EDC cross-linking
- Bacteriostatic
- Toxicity concern



## Live/dead cell assay – 3 hrs post-treatment





#### **Results and Discussion**

- Synthesis of conjugates purification and toxicity concerns
- Time dependent activity Bacteriostatic
- Possible loss of activity (HEWL) against Gram-negative bacteria after covalent conjugation
- Delivery issues Outer membrane (LPS)
- Increase dose MIC





#### Conclusions

- Antibacterial activity of protein-nanoparticle conjugates was not significantly better than control nanoparticles over time
- Reduced charge-directed targeting against Gram-negative bacteria





#### **Future work**

- Reduce toxicity due to synthesis by improved methods of purification
- Alternative means of immobilization using different crosslinkers
- Different antimicrobial protein/peptides more active against Gram-negative bacteria
- Antibody directed targeting





## **Acknowledgments**

- Dr. Alexey Vertegel
- Dr. Vladimir Reukov
- Bionanomaterials Lab
- Department of Bioengineering, Clemson University





